Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: xentuzumab, dusigitumab | 0.81 |
| trials ClinicalTrials.gov | 9 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 169 Parkinson's papers of 26,892 | 0.32 |
| pathways Reactome | 6 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 2353
Sealed predictions
- IGF1 in dopamine neurons, braak+0.66 (p 0.054) → +0.53 (p 0.146)receipt 2360
Swarm cases
receipt 2360: IGF1 in dopamine neurons, braak
- power
- full sample +0.54 (p 0.021, n 18), 95% CI +0.10 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.54 (p 0.021, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.56 (p 0.016, n 18). not the mix.
- skeptic
- leave-one-out range +0.48 to +0.62, sign flips 0; without severely affected donors +0.54 (p 0.021, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IGF1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts